Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The phosphatidylinositol 3-kinase (PI3Kinase)/Protein Kinase B (AKT)/mammalian target of
rapamycin (mTor) pathway plays a role on the development and the venous/lymphatic vascular
organisations.
The investigators want to study the efficacy and the safety of Rapamycin, an mTor inhibitor.
Phase:
Phase 3
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain